Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington’s disease. Laquinimod exerts beneficial activities on both the peripheral immune system and the CNS with distinctive changes in CNS resident cell...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Proc Natl Acad Sci U S A
Egile Nagusiak: Kaye, Joel, Piryatinsky, Victor, Birnberg, Tal, Hingaly, Tal, Raymond, Emanuel, Kashi, Rina, Amit-Romach, Einat, Caballero, Ignacio S., Towfic, Fadi, Ator, Mark A., Rubinstein, Efrat, Laifenfeld, Daphna, Orbach, Aric, Shinar, Doron, Marantz, Yael, Grossman, Iris, Knappertz, Volker, Hayden, Michael R., Laufer, Ralph
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: National Academy of Sciences 2016
Gaiak:
PNAS Plus
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5068259/
https://ncbi.nlm.nih.gov/pubmed/27671624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1607843113
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak